Welcome to our dedicated page for Bioventus SEC filings (Ticker: BVS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Bioventus Inc. (BVS) SEC filings page on Stock Titan brings together the company’s regulatory disclosures from the U.S. Securities and Exchange Commission, with AI-powered summaries to help interpret key points. As a Nasdaq Global Select Market issuer of Class A common stock, Bioventus files current reports on Form 8-K and other periodic reports that provide insight into its operations, governance and capital structure.
In its Form 8-K filings, Bioventus reports material events such as quarterly and year-to-date financial results, including net sales by business (Pain Treatments, Surgical Solutions and Restorative Therapies), net income and the use of non-GAAP measures like Adjusted EBITDA and non-GAAP earnings. These filings often reference accompanying press releases furnished as exhibits, which our AI tools can summarize to highlight segment performance and notable drivers.
Bioventus also uses Form 8-K to disclose financing arrangements, such as the 2025 Credit Agreement that established a $300 million term loan facility and a $100 million revolving credit facility. The filing details interest rate terms, leverage and coverage covenants, maturity dates and the use of proceeds to refinance prior credit facilities. AI analysis can help readers quickly understand how such agreements affect liquidity, leverage and future obligations.
Additional 8-K items cover governance changes, including the appointment of new directors under the terms of a Stockholders Agreement with certain major stockholders. These disclosures explain board composition, designation rights and whether directors receive compensation from the company.
On this page, users can access Bioventus 10-K annual reports, 10-Q quarterly reports, 8-K current reports and Form 4 insider transaction filings as they become available from EDGAR. Real-time updates and AI-generated explanations are designed to make complex filings more accessible, whether you are reviewing segment disclosures, credit facility terms or board changes related to BVS.
Nantahala Capital Management, LLC, together with Wilmot B. Harkey and Daniel Mack, reports beneficial ownership of Bioventus Inc. Class A common stock on a Schedule 13G/A amendment. As of December 31, 2025, they may be deemed to beneficially own 6,047,403 shares, representing 9.03% of the outstanding Class A shares.
The reporting persons have shared power to vote and dispose of all 6,047,403 shares through funds and separately managed accounts controlled by Nantahala, and no sole voting or dispositive power. They state the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of Bioventus.
Bioventus Inc. President and CEO Robert E. Claypoole reported equity award activity involving the company’s Class A common stock. On January 9, 2026, 93,750 restricted stock units were converted into 93,750 shares of Class A common stock at an exercise price of $0. On the same date, 41,717 shares of Class A common stock were withheld at a price of $8.03 per share, typically reflecting shares withheld to cover taxes, leaving Claypoole with 116,997 shares of Class A common stock held directly after these transactions. Following the conversion, he also held 187,500 restricted stock units, each representing a contingent right to receive one share of Class A common stock. These RSUs vest in four equal installments on each of the first four anniversaries of January 10, 2024, subject to his continued service.
Bioventus Inc. (BVS)director of the company and the form is filed by one reporting person.
As of the event date of 11/14/2025, the director reports beneficial ownership of 0 shares of Bioventus Class A common stock, held directly, and no derivative securities are listed in the filing.
Bioventus Inc. reported that its Board of Directors appointed Ajay Dhankhar, PhD, as a Class II director effective November 14, 2025. He will serve until the company’s 2026 annual stockholders meeting or until a successor is selected and qualified. Dr. Dhankhar is currently Chief Corporate Development & Strategy Officer at Smith & Nephew plc and has extensive experience in healthcare advisory and life sciences strategy, including senior roles at Lazard and McKinsey & Company.
The appointment is made under a Stockholders Agreement that allows certain Smith & Nephew stockholders to designate up to two directors, and Dr. Dhankhar is their second designee alongside Philip G. Cowdy. Bioventus states that Dr. Dhankhar will not receive compensation for his Board service and that he has no family relationships with company insiders and no disclosable related-party transactions.
Bioventus Inc. (BVS) reported an insider transaction on a Form 4. A director sold 17,701 shares of Class A common stock on 11/07/2025 at a weighted average price of $7.4151. The filing notes multiple trades executed between $7.36 and $7.43.
Following the sale, the reporting person beneficially owns 56,997 shares, held directly. The transaction is coded “S,” indicating an open‑market or private sale. The filing was made by one reporting person.
Bioventus Inc. (BVS) reported Q3 2025 results. Net sales were $138.651 million, essentially flat year over year. Operating income improved to $11.252 million from $3.647 million, and net income attributable to Bioventus was $3.155 million (diluted EPS $0.05) versus a loss of $5.165 million (diluted EPS $(0.08)) a year ago.
For the first nine months, net sales were $410.187 million and net income attributable to Bioventus was $7.977 million (diluted EPS $0.12) versus a loss of $35.737 million (diluted EPS $(0.56)) last year. Cash from operating activities rose to $36.705 million; cash ended at $42.164 million.
The company refinanced its debt on July 31, 2025 with a new $300 million term loan and a $100 million revolver maturing in 2030. As of quarter end, $25 million was drawn on the revolver, with $75 million available, and Bioventus was in compliance with covenants. It entered interest rate swaps covering $150 million notional at a weighted average fixed rate of 3.60%, recognized as a $785 thousand loss in AOCI. The company paid $19.771 million of Bioness contingent consideration and recorded no further Bioness obligations. Bioventus also recorded an immaterial revision to 2024 equity-based compensation, adjusting prior-period figures.
Bioventus Inc. (BVS) reported results for the three and nine months ended September 27, 2025. The company announced these financial results via a press release furnished as Exhibit 99.1 to a Form 8-K.
The information in Item 2.02, including Exhibit 99.1, is furnished, not filed, and is not subject to Section 18 liabilities, nor incorporated by reference unless expressly stated. The filing also lists Exhibit 104, the cover page Inline XBRL data.
Nantahala Capital Management, LLC and two principals report beneficial ownership of 5,280,842 shares of Bioventus Inc. Class A common stock, representing 7.96% of the outstanding class as of June 30, 2025. The filing states the shares are held by funds and separately managed accounts under Nantahala's control and that Nantahala and its managing members, Wilmot B. Harkey and Daniel Mack, share voting and dispositive power over these shares but have no sole voting or dispositive power. The filing is submitted on a Schedule 13G/A indicating the holdings are in the ordinary course of business and not intended to influence control of the issuer. The document includes the issuer address and signatures dated August 14, 2025.
FAQ
What is the current stock price of Bioventus (BVS)?
What is the market cap of Bioventus (BVS)?
